Inventiva (IVA) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IVA Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.55 |
| 52 Week High | €5.55 |
| 52 Week Low | €2.00 |
| Beta | 0.77 |
| 1 Month Change | -21.37% |
| 3 Month Change | 22.41% |
| 1 Year Change | 46.09% |
| 3 Year Change | -17.92% |
| 5 Year Change | -69.18% |
| Change since IPO | -58.62% |
Recent News & Updates
Recent updates
The Price Is Right For Inventiva S.A. (EPA:IVA) Even After Diving 30%
Oct 31
Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)
Oct 08Need To Know: The Consensus Just Cut Its Inventiva S.A. (EPA:IVA) Estimates For 2025
Sep 04There's Reason For Concern Over Inventiva S.A.'s (EPA:IVA) Massive 27% Price Jump
Aug 15
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency.Need To Know: Analysts Are Much More Bullish On Inventiva S.A. (EPA:IVA)
Apr 02Revenues Not Telling The Story For Inventiva S.A. (EPA:IVA) After Shares Rise 36%
Feb 27Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Sep 27More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%
Jun 18Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why
Jun 14Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking
Mar 19Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S
Jan 16Analyst Forecasts Just Became More Bearish On Inventiva S.A. (EPA:IVA)
May 20Pinning Down Inventiva S.A.'s (EPA:IVA) P/S Is Difficult Right Now
May 05Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)
Apr 01Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt
Jun 15Shareholder Returns
| IVA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -1.4% | -6.2% | -2.2% |
| 1Y | 46.1% | 10.2% | 7.3% |
Return vs Industry: IVA exceeded the French Biotechs industry which returned 9.5% over the past year.
Return vs Market: IVA exceeded the French Market which returned 5.8% over the past year.
Price Volatility
| IVA volatility | |
|---|---|
| IVA Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: IVA's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: IVA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 84 | Andrew Obenshain | inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.
Inventiva S.A. Fundamentals Summary
| IVA fundamental statistics | |
|---|---|
| Market cap | €493.99m |
| Earnings (TTM) | -€311.06m |
| Revenue (TTM) | €16.97m |
Is IVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVA income statement (TTM) | |
|---|---|
| Revenue | €16.97m |
| Cost of Revenue | €817.00k |
| Gross Profit | €16.15m |
| Other Expenses | €327.22m |
| Earnings | -€311.06m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.24 |
| Gross Margin | 95.19% |
| Net Profit Margin | -1,833.03% |
| Debt/Equity Ratio | -1,445.4% |
How did IVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 09:55 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inventiva S.A. is covered by 20 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Nash | Canaccord Genuity |
| Stephanie Lefebvre | Gilbert Dupont |
| Etzer Darout | Guggenheim Securities, LLC |